Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.

Ryo Nishinarita,Shinichi Niwano,Hiroe Niwano,Hironori Nakamura,Daiki Saito,Tetsuro Sato,Gen Matsuura,Yuki Arakawa,Shuhei Kobayashi,Yuki Shirakawa,Ai Horiguchi,Naruya Ishizue,Tazuru Igarashi,Tomoharu Yoshizawa,Jun Oikawa,Yoshinobu Hara,Takafumi Katsumura,Jun Kishihara,Akira Satoh,Hidehira Fukaya,Hiroyuki Sakagami,Junya Ako

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.

2021

Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium–glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and ...

Keywords:

Sodium-Glucose Cotransporter 2 Inhibitor
Canagliflozin
Atrial fibrillation
Pharmacology
Cotransporter
Medicine
Oxidative stress
Clinical trial
Atrial Remodeling

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations